Sarfraz Ahmad – författare

Theranostic Approach for Pancreatic Cancer modulates the biologic properties of stroma in pancreatic cancer by targeting the several chemotherapy resistance mechanisms to impede their malignant property through introducing new strategies and drugs for tackling the disease. It brings information about ongoing research as well as clinical data about pancreatic cancer and provides detailed descriptions about diagnostic and therapeutic options for easy understanding. The book discusses several topics related to pancreatic cancer, such as stem cells, drug resistance and pancreatic tumor microenvironment, the latest developments in chemotherapy for metastatic cancer and chemoprevention, and epigenome as a therapeutic strategy.

Additionally, it encompasses a discussion on theranostic clinical applications for personalized treatment and management of pancreatic cancer. The book is a valuable resource for cancer researchers, oncologists, and several members of the biomedical field who need to understand more about the diagnosis and treatment of pancreatic cancer.

Provides information on the roadblocks of chemotherapy in patients with newly diagnosed and metastatic pancreatic cancer< Discusses treatment options available currently and prospective options for the future Focuses especially on stroma, tumor microenvironment, stem cells, stellate cells, transcription factors, growth factors, and important signaling pathways as already tested types of treatment

Theranostic Approach for Pancreatic Cancer modulates the biologic properties of stroma in pancreatic cancer by targeting the several chemotherapy resistance mechanisms to impede their malignant property through introducing new strategies and drugs for tackling the disease. It brings information about ongoing research as well as clinical data about pancreatic cancer and provides detailed descriptions about diagnostic and therapeutic options for easy understanding. The book discusses several topics related to pancreatic cancer, such as stem cells, drug resistance and pancreatic tumor microenvironment, the latest developments in chemotherapy for metastatic cancer and chemoprevention, and epigenome as a therapeutic strategy.Additionally, it encompasses a discussion on theranostic clinical applications for personalized treatment and management of pancreatic cancer. The book is a valuable resource for cancer researchers, oncologists, and several members of the biomedical field who need to understand more about the diagnosis and treatment of pancreatic cancer.- Provides information on the roadblocks of chemotherapy in patients with newly diagnosed and metastatic pancreatic cancer- Discusses treatment options available currently and prospective options for the future- Focuses especially on stroma, tumor microenvironment, stem cells, stellate cells, transcription factors, growth factors, and important signaling pathways as already tested types of treatment

Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma: Translational and Clinical Outcomes, Volume Three provides comprehensive information about ongoing research and clinical data on liver cancer. The book presents detailed descriptions about diagnostics and therapeutic options for easy understanding, with a focus on precision medicine approaches to improve treatment outcomes. This updated volume discusses topics such as clinical and safety assessment of HCC patients, liver transplantation as a therapeutic option, immunotherapy interventions, and image-based surveillance. In addition, it discusses immunohistology of HCC-enabled precision medicine and artificial intelligence for hepatocellular carcinomas.

This is a valuable resource for cancer researchers, oncologists, graduate students, hepathologists and members of biomedical research who need to understand more about liver cancer to apply in their research work or clinical setting.

Provides best practices for the management of hepatocellular carcinoma in the clinical setting Discusses emerging treatment approaches based on artificial intelligence and precision medicine tools and techniques Brings updated information on international clinical trials for the treatment of HCC

Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma: Translational and Clinical Outcomes, Volume Three provides comprehensive information about ongoing research and clinical data on liver cancer. The book presents detailed descriptions about diagnostics and therapeutic options for easy understanding, with a focus on precision medicine approaches to improve treatment outcomes. This updated volume discusses topics such as clinical and safety assessment of HCC patients, liver transplantation as a therapeutic option, immunotherapy interventions, and image-based surveillance. In addition, it discusses immunohistology of HCC-enabled precision medicine and artificial intelligence for hepatocellular carcinomas.This is a valuable resource for cancer researchers, oncologists, graduate students, hepathologists and members of biomedical research who need to understand more about liver cancer to apply in their research work or clinical setting.- Provides best practices for the management of hepatocellular carcinoma in the clinical setting- Discusses emerging treatment approaches based on artificial intelligence and precision medicine tools and techniques- Brings updated information on international clinical trials for the treatment of HCC

Immune Therapy for Pancreatic and Colon Cancer expands the knowledge on pathways, immune modulators, immune check points, and monoclonal antibodies that can lead to appropriate cancer treatment. With a strong focus on the development of immune therapies to improve the survival rates of pancreatic and colon cancer, this book also shows the latest trends in immune targeted approaches for cancer treatment. Sections describe the role of and the immune response to pancreatic and colon cancer, gives insights to past and current immunotherapies, including metabolic reprogramming, immune blockade therapy and immune modulation.This book is a valuable resource for health professionals, scientists and researchers, students, and all those who wish to broaden their knowledge of the advances in immunotherapy in pancreatic and colon cancer, inspire them and guide their design of novel experimental projects and translational studies.Aims to incorporate diverse and novel immunotherapeutic strategies, targeting a wide array of tumor-induced immune escape mechanismsElucidates both past and current differences in immunotherapies, while also including strategies based on monoclonal antibodies' vaccine, and oncolytic virus-related immunotherapiesProvides an updated understanding of the how resistance breaks with immunotherapy in both pancreatic and colon cancer

Immune Therapy for Pancreatic and Colon Cancer expands the knowledge on pathways, immune modulators, immune check points, and monoclonal antibodies that can lead to appropriate cancer treatment. With a strong focus on the development of immune therapies to improve the survival rates of pancreatic and colon cancer, this book also shows the latest trends in immune targeted approaches for cancer treatment. Sections describe the role of and the immune response to pancreatic and colon cancer, gives insights to past and current immunotherapies, including metabolic reprogramming, immune blockade therapy and immune modulation.This book is a valuable resource for health professionals, scientists and researchers, students, and all those who wish to broaden their knowledge of the advances in immunotherapy in pancreatic and colon cancer, inspire them and guide their design of novel experimental projects and translational studies.- Aims to incorporate diverse and novel immunotherapeutic strategies, targeting a wide array of tumor-induced immune escape mechanisms- Elucidates both past and current differences in immunotherapies, while also including strategies based on monoclonal antibodies'' vaccine, and oncolytic virus-related immunotherapies- Provides an updated understanding of the how resistance breaks with immunotherapy in both pancreatic and colon cancer